Cord Blood News Volume 12.09 | Mar 12 2020

TOP STORY

An EBNA3A-Mutated Epstein-Barr Virus (EBV) Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model

Investigators compared the phenotypes of an EBNA3A-mutated EBV, versus wild-type EBV, in a cord blood-humanized mouse model. [J Virol] Abstract

(Ranked by impact factor of the journal)

Therapeutic Mechanism of Cord Blood Mononuclear Cells via the IL-8-Mediated Angiogenic Pathway in Neonatal Hypoxic-Ischemic Brain Injury

Human umbilical cord blood mononuclear cell administration restored the sequential downstream signaling axis of p-p38/p-MAPKAPK2, NFκB, and angiogenic factors, which were downregulated by hypoxic-ischemic brain injury. [Sci Rep] Full Article

Autologous Cord Blood Cell Therapy for Neonatal Hypoxic-Ischemic Encephalopathy: A Pilot Study for Feasibility and Safety

Investigators conducted a single-arm clinical study to examine the feasibility and safety of intravenous infusion of autologous umbilical cord blood cells for newborns with hypoxic-ischemic encephalopathy. [Sci Rep] Full Article

Effect of Graft-versus-Host Disease on Outcomes after Pediatric Single Cord Blood Transplantation

Pediatric patients aged 0-15 years with acute leukemia or myelodysplastic syndrome who underwent their first unrelated cord blood (UCB) transplantation were selected from the Japanese registry. Fifty percent of the patients received a UCB unit containing more than 5.0×10⁷/kg total nucleated cells. [Bone Marrow Transplant] Abstract

A Protocol for the Isolation, Culture, and Cryopreservation of Umbilical Cord-Derived Canine Mesenchymal Stromal Cells: Role of Cell Attachment in Long-Term Maintenance

A stepwise process was used to optimize canine MSCs isolation, expansion, and cryopreservation utilizing canine umbilical cord-derived MSCs. The culture protocol utilized coating of tissue culture surfaces that increased cellular adherence, increased colony-forming units-fibroblast efficiency, and decreased population doubling times. [Stem Cells Dev] Abstract

Induction of Antitumor Immunity by Exosomes Isolated from Cryopreserved Cord Blood Monocyte-Derived Dendritic Cells

The authors tested the ability of cryopreserved umbilical cord blood mononuclear cell-derived dendritic cells and their exosomes to prime allogeneic T cell proliferation and allogeneic peripheral blood mononuclear cell cytotoxicity against A549 lung cancer cells. [Int J Mol Sci] Full Article

Successful Umbilical Cord Blood Transplantation with Reduced-Intensity Conditioning for Acute Myeloid Leukemia in a Child with Shwachman-Diamond Syndrome

Scientists report a case of a seven-year-old girl with Shwachman-Diamond syndrome who developed acute myeloid leukemia with monosomy 7. She was successfully treated with chemotherapy followed by unrelated cord blood transplantation with reduced-intensity conditioning consisting of fludarabine, melphalan, and high-dose cytarabine without significant toxicity. [J Pediatr Hematol Oncol] Abstract

Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News.

Potential of Mesenchymal Stem Cells Alone, or in Combination, to Treat Traumatic Brain Injury

The authors focus on different therapeutic approaches of traumatic brain injury and the present status of the clinical trials. [CNS Neurosci Ther] Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (Elotuzumab) plus Revlimid (Lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma

Bristol Myers Squibb company announced topline results from ELOQUENT-1, a Phase III, randomized, open-label trial evaluating the combination of Empliciti plus Revlimid and dexamethasone, versus Revlimid and dexamethasone alone, in patients with newly diagnosed, previously untreated multiple myeloma who are transplant ineligible. [Bristol Myers Squibb Company] Press Release

Ascentage Pharma Announces Clearances for Three Phase Ib/II Clinical Studies of APG-2575 in China and the US, Beginning Simultaneous Clinical Development in Three Hematologic Malignancy Indications

Ascentage Pharma announced that two clinical studies of APG-2575, a novel Bcl-2 selective inhibitor being developed by Ascentage Pharma, have recently received clearances from the FDA. [Ascentage Pharma (PR Newswire Association, LLC.)] Press Release

Universities Are Forging Ties with the FBI as US Cracks Down on Foreign Influence

US universities are forging closer ties with FBI agents, encouraging scientists to disclose foreign sources of research funding, and tightening restrictions on researchers’ travel. [Nature News] Editorial

Hundreds of Scientists Have Peer-Reviewed for Predatory Journals

Hundreds of scientists who post their peer-review activity on the website Publons say they’ve reviewed papers for journals termed ‘predatory’, an analysis has found. The site hosts at least 6,000 records of reviews for more than 1,000 predatory journals. [Nature News] Editorial

NEW International Society for Experimental Hematology (ISEH) 2020
August 20-23, 2020
New York, New York, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Researcher – Hematologic Malignancies (Northwestern University)

NEW Postdoctoral Position – Hematopoietic Stem Cell Biology (Columbia University Medical Center)

NEW Postdoctoral Positions – Cancer Research (Moores Cancer Center, UC San Diego)

NEW Team Leader – Clonal Evolution in Leukemias (Institute of Cancer Research)

Postdoctoral Researcher – Leukemia (Universitätsklinikum Carl Gustav Carus Dresden)

Postdoctoral Scientist – Stem Cell Biology (Cancer Research UK Manchester Institute)

Research Technician – Graft versus Host Disease (Fred Hutchinson Cancer Research Center)

Laboratory Director – Cord Blood Processing (PerkinElmer)

Research Associate – Cell Culture (Rogosin Institute)

Tenure-Track/Tenured Faculty Positions – Biomedical Science (Southern University of Science and Technology)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.